Abstract Skin biopsy is a valuable diagnostic tool for smallfiber-predominant neuropathy by the quantification of intraepidermal nerve fiber density (IENFD). It has the unique advantage of being a minimally invasive procedure with the potential for longitudinal evaluation of both sensory and autonomic fibers. Unmyelinated small fibers are not otherwise quantified objectively with such a level of sensitivity as has been reported with IENFD. Recent advances include an expansion of the skin punch biopsy technique to evaluate larger myelinated fibers and mechanoreceptors, and recent work has also focused on additional methods of quantifying dermal fibers and densely innervated autonomic structures. This review discusses current work using skin biopsy for the pathologic analysis of peripheral nerve fibers in neuropathy of various causes as well as its use in clinical trials.
Introduction
The discovery of protein gene product (PGP) 9.5 as a ubiquitin hydrolase component of axons [1] provided unequivocal evidence of the presence of unmyelinated nerve fibers in the epidermis and its detection has since become a vital tool for qualitative and quantitative studies of cutaneous nerve fiber densities and morphology [2] . Skin punch biopsy is a minimally invasive procedure and is particularly suitable for detecting nociceptive small fibers, a population of fibers largely undetectable though nerve conduction studies and sural nerve biopsies [3] .
Skin punches are typically between 2 and 5 mm in diameter and extend to a depth of approximately 4 mm, where larger myelinated fibers and autonomic structures also reside. Glabrous, nonhairy skin contains a dense population of mechanoreceptors and large myelinated afferent fibers that can reveal additional pathologic changes in myelinating Schwann cells and nodal and internodal architecture [4] .
Both less invasive and noninvasive methods of sampling and imaging cutaneous structures have also been developed to evaluate small fibers and mechanoreceptors. Small-fiber density in the epidermis may be evaluated by the skin blister technique, in which a negativepressure vacuum is applied to a region of the skin so that the epidermis may be separated from the dermis for epidermal fiber quantification [5] . Recently, in vivo reflectance confocal microscopy has been developed as a noninvasive technique to evaluate mechanoreceptor Meissner corpuscle density [6, 7] .
Since the advent of the panaxonal PGP 9.5 antibody and the pioneering publications reporting the use of skin punches and immunohistochemistry for the analysis of intraepidermal nerve fiber density (IENFD) [8] , there has been an expansion of the technique to expound on sensory and autonomic fibers as well as mechanoreceptors and large dermal fibers. This review provides a summary of recent work using glabrous or hairy skin punch biopsy to reveal sensory and autonomic nerve fiber pathologic changes.
Methods of Processing
Tissue processing methods of skin punches depend on subsequent visualization techniques. For immunohistochemistry, fixation is typically done with paraformaldehyde. Immunoperoxidase staining allows bright-field quantification, and immunofluorescent staining can be coupled with either epifluorescence microscopy or confocal microscopy. Species-specific secondary antibodies may visualize multiple antigen-bound primary antibodies selected in a number of combinations to investigate neuronal structures, cutaneous structures, and neurotransmitters relevant to the sensory system as well as the autonomic system (Table 1) . In clinical practice, bright -ield immunohistochemistry is most commonly used [9] . Although confocal microscopy is more technically difficult and time-consuming, it allows the acquisition of images with greater optical z resolution than is possible through widefield microscopy. Combining a z stack of cutaneous structures taken throughout thick sections into a three-dimensional reconstruction allows the visualization of large structures wholly in focus (Fig. 1) .
Cutaneous ultrastructure may be visualized by electron microscopy (EM), which requires fixation with glutaraldehyde followed by osmification and Epon embedding. Thin and ultrathin sections may be cut with a microtome and then contrasted by a standard EM protocol [10] . This method makes possible the quantification of myelin thickness (G ratio) and organelle localization. For example, skin biopsy has been used for the localization of mitochondria in axonal swellings of patients with diabetes [11] and also the accumulation of intra-axonal mitochondria in Charcot-MarieTooth disease type 1A [10] .
Immuno-EM has also been used in skin biopsy studies to quantify protein expression [10] . Protein content may also be quantified by Western blot; however, the relatively small amount of neuronal tissue in the skin requires larger or multiple biopsies to be taken solely for this technique. Immuno-EM has an advantage over Western blotting in that protein expression can be localized to specific cellular structures. In short, conjugation of antibodies to electron-dense gold particles may be used to calculate the percent expression according to the number of conjugated particles divided by the total area examined. For example, peripheral myelin protein 22 expression was calculated as a percent composition of the compact myelin of a dermal nerve [10] . Various techniques and some of their applications to skin biopsy are summarized in Table 2 .
Quantification
Standard procedures of intraepidermal nerve fiber counting have been thoroughly reviewed [12] . In short, previous methods were adapted to include only fibers that intersect the dermal-epidermal basement membrane, excluding more superficial fragments. This method has been well documented to have high interobserver reliability and reproducibility between laboratories [13] . Although the skin blister method is less invasive than punch biopsies, it has been less widely used because it is a longer procedure, requiring 30-90 min for blister formation. Even so, good correlations have been reported between both sampling methods in regard to epidermal fiber density [14] . The subepidermal neural plexus runs parallel to the skin's surface and is a dense nerve bundle from which individual cutaneous nerves branch; it, like many densely innervated structures, has proven difficult to quantify, although marked disease-related reductions have been noted [15, 16] . For evaluation of innervation of the subepidermal neural plexus, semiquantitative methods may be used that are based on assigning numerical categories corresponding to degrees of innervation ranging, for example, from hyperinnervation (+1) to none whatsoever (−4) [17] . Recently, a novel quantification method of "manual morphometry" as well as unbiased stereologic techniques were applied to quantification of the similarly dense (autonomic) innervation of sweat glands, suggesting an alternative to quantifying such densely innervated dermal structures [18] . Furthermore, in a comparative study, semiquantitative methods had poor reliability and low correlation to neuropathy scores, whereas both automated application and manual application of stereology-based techniques were reliable and correlated well with IENFD and examination findings [19•] .
Other recent quantification methods include the analysis of a single frame of a confocal z stack, thereby selecting a manageable sample of autonomic fibers of the arrector pili muscle [20•] . Quantification of fluorescence intensity can also be used for such densely innervated structures [21] , although this method is generally accepted to be at high risk Fig. 1 Protein gene product 9.5 staining of axons (black) in a 50-μm-thick section of skin depicting the rich sensory and autonomic innervation of hairy skin (a). Autonomic fibers innervate an arrector pili muscle and a sweat gland (arrows). Sensory fibers are seen at the base of the hair follicle and also branching from the subepidermal neural plexus, crossing the dermal-epidermal basement membrane (arrowheads) to innervate the epidermis (b) 
Utility of Skin Biopsy in Detecting Neuropathy
Skin biopsy has become a common method to evaluate patients presenting with small-fiber-predominant polyneuropathy. It first became widely used in HIV-associated polyneuropathy, which frequently does not exhibit nerve conduction study abnormalities until later in the course of the disease [28] . IENFD was used successfully as an end-point measure in several prospective cohorts and clinical trials evaluating HIV neuropathy [29] [30] [31] . McArthur et al. pioneered both normative data references [32] and reliability studies [13] . A worldwide normative study was also recently published [33] .
Diabetes is the leading cause of peripheral neuropathy and typically presents as distal, symmetric small-fiberpredominant neuropathy [34] . Early work using skin biopsy established the length-dependent nature of diabetic polyneuropathy by biopsying distal and proximal sites in parallel [32] . The axonal regeneration marker growth-associated protein 43 has also been suggested as a biomarker of the deficiency of regeneration found in the peripheral nerves of individuals with type II diabetes [35] .
There is a known involvement of large fibers in diabetic neuropathy as well, although work by Singleton and Smith [36] has suggested that C-fiber involvement may occur earlier than myelinated fiber involvement on the basis of several studies of asymptomatic diabetic patients and patients with impaired glucose tolerance and neuropathy. It is clear that histological studies uniformly show greater neuropathic changes than electrophysiologic measures, as nerve biopsy also has greater sensitivity than nerve conduction studies for detecting peripheral nerve abnormalities in diabetes [37] . This may be true for medication-induced neuropathy as well. The findings of nerve conduction studies were shown to change minimally even over relatively long follow-up times (more than 5 years) [38, 39] . Owing to the risk of morbidity, sural nerve biopsies are rarely done diagnostically, which has limited pathologic assessment of myelinated fibers. Nerve fiber density was more sensitive than nerve conduction in detecting neuropathy from nitrofurantoin, flecainide, and oxaliplatin [40] [41] [42] and is being used as an end point for several studies of chemotherapy-induced neuropathy [43, 44] . Glabrous skin, in particular, has a high density of dermal myelinated fibers, and could be developed as an alternative for pathologic evaluation of large myelinated fibers in diabetic patients [45••, 46, 47•] .
Despite a practice parameter published in 2009 by the American Academy of Neurology citing only a level C recommendation [48] , skin biopsy is widely used to evaluate patients for both small-fiber-predominant polyneuropathy and distal symmetric neuropathy in which the findings of nerve conduction studies are normal. The decreased sensitivities cited by England et al. [48] may be partially due to using only one site for IENFD [49] , or the inclusion of heterogeneous groups of patients. In addition, previous studies have not included patients with neuropathic pain due to other conditions as controls [48] .
The advantages of skin biopsy include its wide availability (multiple laboratories offer IENFD evaluation), potential for longitudinal analysis of nerve fibers, and the objective nature of quantifying sensory fibers. Quantitative sensory testing has been demonstrated to be highly subjective [50] and also much less sensitive than IENFD quantification, with most measures detecting only relatively large changes in fiber densities (more than 12 fibers per millimeter) [51] . In another recent study [52] , significant reductions in the numbers of PGP 9.5-immunoreactive fibers as well as TRPV1-immunoreacive fibers were reported in diabetic patients after a relatively short 6-month skin biopsy followup, providing further support for the sensitivity of IENFD in tracking neuropathy.
Until recently, skin biopsies have not been performed in disorders affecting mainly myelinated nerves. Recent efforts have been made to quantify myelinated fibers and identify segmental demyelination [10] , inflammation [53] , and antimyelin-associated glycoprotein [54] . GBS has traditionally been viewed as a largely myelinated fiber disorder, yet dysautonomia has long been recognized as a common feature. Skin biopsy in GBS patients revealed decreased IENFD and that sudomotor density was decreased in five of 17 patients [55] . Hypomyelination and onion bulb formation were identified in skin biopsies of Charcot-Marie-Tooth neuropathy patients [10, 56] . Also, hallmark segmental demyelination was identified in patients with CIDP compared with controls [10] . Realtime PCR can also be used to demonstrate upregulation of inflammatory markers in CIDP [53] . Perivascular infiltration in vasculitic neuropathy has also been appreciated in skin biopsies [57] .
Use of Skin Biopsy in Detecting Voltage-Gated Channels
Skin biopsy has recently been used to detect changes in voltage-gated sodium channel expression in patients with small-fiber neuropathy. There are nine different subtypes of sodium channels, several of which (1.2, 1.6, 1.7, 1.8) are found in peripheral nerves [58] . Mutations in subtype 1.7 have been associated with erythromelalgia and insensitivity to pain [59, 60] . SCN9A codes for Na v 1.7 and has conclusively been shown to have a crucial role in pain [61] . Patients screened for small-fiber neuropathy by skin biopsy and quantitative sensory testing underwent genetic testing confirming SCN9A mutations [62, 63] . Cell culture studies (from dorsal root ganglion cells with identical Na v 1.7 mutations as in patients) demonstrate increased excitability with current clamp models [64] . Several patients also had autonomic symptoms [62, 63] . Na v 1.8 upregulation has been observed in animal models of neuropathic pain [65] . Furthermore, dysregulation of Na v 1.6 and Na v 1.8 has been observed in diabetic rat models [66] . In short, known disruptions of voltage-gated channels have been reported in humans and in animal models of painful neuropathy. Skin biopsy could play an important role in further investigations.
Applications of Skin biopsy in Clinical Research
There are several advantages to studying cutaneous nerves. First, skin biopsies are repeatable, unlike nerve biopsies, which allow the investigator multiple time points over the course of a study to quantify innervation. Skin biopsy with nerve fiber density measurements has been used as a secondary endpoint for several studies, including lifestyle intervention in prediabetic neuropathy [67] , HIV peripheral neuropathy [68, 69] , and Fabry disease [70] . Secondly, axonal regeneration is also possible to observe within reasonable time periods (months) in human participants [71] ; which may represent a more appropriate clinical endpoint than current density measures or neurophysiologic measures. The two axotomy models used currently have been chemical denervation using capsaicin [71] and excision axotomy in which a small punch is performed first followed by a larger, encompassing punch taken at a later time point [72•] . Chemical axotomy using capsaicin can also be used to evaluate regeneration of autonomic fibers [73••] .
Applications of Skin Biopsy in Autonomic Disorders
The use of skin biopsy has been expanded to multiple autonomic disorders as the quantification of autonomic fibers has become more specific; however, it may still be underused in these disorders. The commonest autonomic disorder in which skin biopsy has been used to quantify autonomic innervation is diabetic neuropathy. Correlation of the loss of sudomotor fibers with hyperglycemia has been reported [74] . Initial quantification of both pilomotor and sudomotor denervation was performed in diabetic patients [18, 20•] . It may also be helpful in chemotherapy-induced autonomic neuropathy. A case report of toxic neuropathy with bortezomib therapy in three patients showed not only loss of IENFD but also decreased numbers of adrenergic fibers and sudomotor fibers [75] .
Parkinson's disease (PD) is a common cause of autonomic failure, which paradoxically affects peripheral autonomic fibers in addition to possible central fibers in the locus ceruleus and nucleus of the vagus [76] . Decreased sudomotor and pilomotor muscle innervation has been documented in patients with less than 15 years of PD [77] and may precede the development of autonomic symptoms. Increased level of α-synuclein has been identified in chest skin but not distal skin from postmortem samples of PD patients compared with control patients [78] . IENFD (somatic C fibers) is reduced in PD patients compared with age-matched controls, suggesting additional sensory involvement as well [79] .
Multiple system atrophy (MSA), a severe neurodegenerative disease presenting with autonomic failure coupled with parkinsonism or cerebellar degeneration, has a mean life expectancy of 5-9 years [80] . MSA has been shown to have relatively normal skin autonomic innervation compared with pure autonomic failure [81] , another cause of severe autonomic dysfunction. Pure autonomic failure is an idiopathic disorder with restricted accumulation of α-synuclein in peripheral autonomic neurons not associated with other movement disorders [82] . It is tantalizing to suggest that skin biopsy may be a possible tool to differentiate pure autonomic failure and PD with autonomic symptoms from MSA, which has a mostly central or preganglionic autonomic involvement.
Postural tachycardia syndrome is a syndrome most likely including a heterogeneous group of disorders with a common occurrence of significant orthostatic tachycardia without concurrent drop in blood pressure. Skin biopsy in patients with postural tachycardia syndrome showed normal skin norepinephrine concentration but with some morphologic abnormalities in the somatic C fibers in three of the eight patients studied [83] . No further studies have been performed in this population.
Limitations of the Procedure
Several limitations of skin biopsy have been secondary to multiple factors. One is the heterogeneous nature of peripheral neuropathy-it is possible that some disorders have greater Cfiber degeneration than others, which may bias findings. Another limitation has been the lack of uniform correlation of skin biopsy results with other neuropathy end points [43, 49, 84] .
The greatest limitation has been the lack of specific identifying characteristics for the cause of neuropathy. Histological evaluation has not provided a way to differentiate between the causes of disease. This may be due to a "final common pathway" shared by all neuropathies, or may be due to a lack of specific neuronal markers. Except in clinical trial settings, the findings of skin biopsy rarely change clinical management, especially in disorders such as diabetes where the cause of neuropathy is known, even if the pathogenesis is not.
The skin has a rich innervation of sensory and autonomic fibers, but the relatively high ratio of connective tissue to neural tissue limits some methods of analysis. For example, protein quantification by Western blot requires a larger skin biopsy that what is typically sampled for immunohistochemistry alone. Immuno-EM is an alternative method; however, there is a high degree of uncertainty in ultrathin sectioning as to whether neural tissue is being targeted. Also, large samples of nerve likely have better sensitivity for conditions also affecting vessels and connective tissue such as amyloidosis, vasculitis, leprosy, etc.
Conclusions
In summary, skin biopsy has a unique role in identifying sensory and autonomic neuropathy given its greater sensitivity for identifying pathologic changes in unmyelinated fibers. Further use of skin biopsy in clinical trial end points is expected. The advantage of using skin biopsy continues to be its ease of sampling, repeatability, and possibilities for investigating nerve regeneration. Advances in specific biomarkers would be ideal for discriminating between various causes of peripheral and autonomic neuropathies. Evaluation of autonomic fiber and large-fiber innervation in addition to small sensory fibers will provide more comprehensive descriptions of neuropathic changes and potentially broaden the use skin biopsy as a biomarker of peripheral neuropathy. 
